ARTERIAL METHEMOGLOBIN LEVEL PREDICTS THERAPEUTIC EFFECTIVENESS OF THE PDE-5 INHIBITORS IN PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION  by Ono, Tomohiko et al.
E1462
JACC April 5, 2011
Volume 57, Issue 15
  VASCULAR DISEASE
ARTERIAL METHEMOGLOBIN LEVEL PREDICTS THERAPEUTIC EFFECTIVENESS OF THE PDE-5 
INHIBITORS IN PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 10:00 a.m.-11:15 a.m.
Session Title: Venous Thrombosis/Pulmonary Embolism/ Pulmonary Hypertension
Abstract Category: 12. Venous Thrombosis/Pulmonary Embolism/Pulmonary Hypertension
Session-Poster Board Number: 1010-132
Authors: Tomohiko Ono, Yuichi Tamura, Takashi Kawakami, Masaharu Kataoka, Motoaki Sano, Toru Satoh, Keiichi Fukuda, Keio University School of 
Medicine, Tokyo, Japan, Kyorin University Faculty of Medicine, Tokyo, Japan
Background The PDE5 inhibitors are emerging as novel therapeutic tools in patients with idiopathic pulmonary arterial hypertension (PAH). 
However, the response to the PDE5 inhibitors varies among patients. The PDE inhibitor augments and prolongs the vasodilator effect of NO. Thus, 
therapeutic effectiveness of the PDE inhibitors relies on the ability of pulmonary vascular endothelial cells to produce NO. Hemoglobin binds to NO 
with great affinity and forms methemglobin by oxidation in the erythrocyte. We hypothesized that methemoglobin level is correlated positively with 
the capacity of NO production in pulmonary vascular endothelial cells and can be used as a biomarker for prediction of therapeutic response to the 
PDE5 inhibitors.
Methods Twenty three idiopathic PAH patients (WHO functional class II or III) who underwent right heart catheterization received the PDE5 
inhibitors [sildenafil (n=21), tadalafil (n=2)]. None of them are smokers or taking endothelin receptor antagonist. Arterial methemoglobin level was 
measured before administration of the PDE5 inhibitors. Hemodynamics were reassessed after a half year observation period (mean following period 
was 177.5 days).
Results Mean methemoglobin level of the patients was 0.7±0.45 % (normal range was 0.2 - 0.6 %). The reduction of mean pulmonary arterial 
pressures (mPAP) by the PDE5 inhibitors were significantly well correlated with the methemoglobin levels (r=0.46, p=0.027). The patients with high 
methemoglobin level (≥1.0%) exhibited significantly superior reduction of mPAP than patients with low methemoglobin level (15.5±5.86 mmHg vs 
8.18±2.00 mmHg, p=0.04). The reduction of pulmonary vascular resistance also tended to superior in high methemoglobin level group than low 
level group (6.41±4.08 Wood’s Unit vs 4.56±1.30 Wood’s Unit, p=0.11).
Conclusion Measuring methemoglobin level is feasible for prediction of responder and non-responder to the PDE5 inhibitors in patients with 
idiopathic PAH.
